1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. LUPIN LTD.
Lupin Ltd.
NSE: LUPIN | BSE: 500257

Lupin Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutLupin Limited is a multinational pharmaceutical company with a significant presence in the global generics market and a strong leadership position in India. The company focuses on developing and delivering a wide range of branded and generic formulat... Read More
US FDA Inspections
Ask AI about Lupin
2011.0021.10(1.06%)

52W Low on Oct 23, 2026

779.7K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Lupin is on 03 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
39.3 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

22

S

6

W

6

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

19Positive4Negative

Pass in checklist82.6%

045
55
100

PE Valuation Check

Right Now
Undervalued
249.4%
1 Year Forward
Undervalued
176.4%
INSIGHTHigh 5Yr PE Avg of 58.1 may distort upside values.

Lupin Stock Price Analysis

Day Price Range

1.1% 1 Day return
2011 (LTP)
1,9742,021.8
LowHigh

Week Price Range

4.3% 1 Week return
2011 (LTP)
1,912.42,021.8
LowHigh

Month Price Range

-2.0% 1 Month return
2011 (LTP)
1,892.92,071.7
LowHigh

52 Week Price Range

3.4% 1 Year return
2011 (LTP)
1,892.92,529.5
LowHigh
View full Price History/Seasonality

Lupin Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Lupin's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

CURRENT EPS
116.4
AVG. ESTIMATE
96.3
LOW ESTIMATE
90.2
HIGH ESTIMATE
106.1
CURRENT EPS
AVG. ESTIMATE
Miss

EPS is expected to reduce by 17.3% in FY27

Consensus Recommendation

36 ANALYST Recommendations
HOLD

The consensus recommendation from 36 analysts for Lupin is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Lupin Technical Analysis

Lupin EMA & SMA

Bullish+2
5 bullish, 3 bearish
Bullish5
Bearish3
5 Day1982.2
10 Day1972.9
12 Day1973.5
20 Day1986.1
26 Day2000.9
50 Day2065.2
100 Day2146.3
200 Day2175.5

Lupin Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202658.3%
Week56.6%
Month59.2%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Lupin Resistance and Support

2002.27
Pivot
First Resistance2030.5
Second Resistance2050.1
Third Resistance2078.3
First Support1982.7
Second Support1954.5
Third Support1934.9
Day RSI51.4
Day MACD-27.4
Day MFI56.4
Day MACD Signal Line-40.1

Lupin Beta

1 Month1
1 Year0.5
3 Month0.6
3 Year0.6

Lupin Price Change Analysis

↓-2%
Over 1 Month
LowHigh
1892.92071.7
↓-16.9%
Over 3 Months
LowHigh
1892.92440
↓-13%
Over 6 Months
LowHigh
1892.92529.5
↑3.4%
Over 1 Year
LowHigh
1892.92529.5
All Technicals →

Lupin Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Lupin Investments Private LimitedPromoter207,194,39045.3 %
Hdfc Mutual Fund-Hdfc Arbitrage FundDii21,400,3754.7 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Lupin Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell14 Oct 20251937.5060,035NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase14 Oct 20251937.5060,035NSE
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell13 Oct 2025197781,892NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase13 Oct 2025197781,892NSE
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDBlockSell14 Jul 20251894.7052,861BSE
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDBlockPurchase14 Jul 20251894.7052,861BSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20241449.20747,956BSE
SOCIETE GENERALEBlockPurchase25 Jan 20241449.20747,956BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell14 Nov 2022747228,477NSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase14 Nov 2022747228,477NSE
All deals
All insider trades

Lupin Corporate Actions

Lupin Dividend history and yield

Lupin dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Lupin dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
117 Jul 2026
18FINAL17 Jul 2026Equity Share
225 Jul 2025
12FINAL25 Jul 2025Equity Share
316 Jul 2024
8FINAL16 Jul 2024Equity Share
414 Jul 2023
4FINAL14 Jul 2023Equity Share
514 Jul 2022
4FINAL15 Jul 2022Equity Share

Lupin Bonus shares

Lupin bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
111 Aug 2006
1:114 Aug 2006

Lupin Board Meetings

Lupin past and upcoming board meetings.

#Ex-Date
PurposeNotes
103 Nov 2026
Quarterly Results-
206 Aug 2026
Quarterly Results-
307 May 2026
Audited Results & Final Dividend-
412 Feb 2026
Quarterly Results-
506 Nov 2025
Quarterly Results & OthersTo consider other business matters.

Lupin Stock Split

Lupin stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
127 Aug 2010
10230 Aug 2010
All Corporate Actions

Lupin Research Reports

Lupin research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
109 Aug 2026Deven Choksey24442300Accumulate6.26%-12.57%pdf
208 Aug 2026ICICI Securities Limited
Reco
Target
22002363.5Sell-6.92%-14.91%pdf
307 Aug 2026Motilal Oswal25002363.5Neutral5.78%-14.91%pdf
405 Aug 2026Deven Choksey
Target
24882388Hold4.19%-15.79%pdf
503 Jun 2026Geojit BNP Paribas
Target
26062249.8Buy15.83%-10.61%pdf
All Reports of Lupin

Lupin Corporate Filings

Lupin BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
24 Oct 2026
Lupin Ltd - 500257 - General Updates
U.S. FDA has concluded an inspection at Company''s manufacturing facility located in Goa, India.
PDF
23 Oct 2026
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation of allotment of 3,033 equity shares under ESOP.
PDF
23 Oct 2026
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Appoints Brian Savage as President, Chief Legal Officer.
PDF
22 Oct 2026
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation about the Appointment of Senior Management Personnel.
PDF
19 Oct 2026
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation regarding Grant of 40,157 Stock Options under Lupin Employees Stock Option Scheme 2025.
PDF
VIEW ALL

Lupin DocumentsAsk MarketMind AI

Lupin Earnings Call

Lupin earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
12 Aug 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
07 Aug 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
14 May 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
17 Feb 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
12 Nov 2025Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAi summaryLink
view all

Lupin Annual Reports

Lupin financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Lupin Credit Ratings

Lupin credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
07 Jul 2026icra ratingsLupin Manufacturing Solutions LimitedRating reaffirmedLink
07 Jul 2026icra ratingsLupin LimitedRating reaffirmedLink
07 Jul 2026icra ratingsLupin Life Sciences LimitedRating reaffirmedLink
07 Jul 2026icra ratingsLupin Diagnostics LimitedRating reaffirmedLink
18 Jan 2026icra ratingsLupin Manufacturing Solutions LimitedRating reaffirmed; rated amount enhancedLink

Lupin Investor Presentations

Lupin investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
06 Aug 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Aug 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
07 May 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
12 Feb 2026Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Nov 2025Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Lupin - Company Profile

Lupin Management Structure

Lupin management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Vinita GuptaExecutive Director,Chief Executive Officer266.29Mar 26
Ramesh SwaminathanExecutive Director,Global Chief Financial Officer,Chief Risk Officer,Head(Corporate Affairs)106Mar 26
Mr. Christoph FunkeChief Technical Officer(Operations)-Mar 26
Mr. Rajeev SibalPresident(India Region Formulations)-Mar 26
Mr. Yashwant MahadikPresident(Global Human Resources)-Mar 26
Dr. Cyrus KarkariaPresident(Biotech Business)-Mar 26
Dr. Sofia MumtazPresident(Legal.,Compliance)-Mar 26
Dr. Ranjana PathakChief Quality Officer-Mar 26
Dr. Abdelaziz ToumiChief Executive Officer(Subsidiary Company)-Mar 26
Mr. Thierry VollePresident(EMEA,Emerging Markets)-Mar 26
Dr. Fabrice EgrosPresident(Corporate Development)-Mar 26
Dr. Shahin FesharakiChief Scientific Officer-Mar 26
Mr. Spiro GavarisPresident(Generics)-Mar 26
Mr. Claus JepsenPresident(Global,Specialty Care)-Mar 26
Amit Kumar Gupta.Company Secretary,Compliance Officer-Mar 26

Lupin Board of Directors

Lupin Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Vinita GuptaExecutive Director & CEO2665Mar 26
Nilesh GuptaED / MD / Promoter1278Mar 26
Ramesh SwaminathanED / Global CFO / CRO / Head1060Mar 26
Mark D McDadeIndependent Non Exe. Director190Mar 26
Alfonso ZuluetaIndependent Non Exe. Director171Mar 26
Jeffrey KindlerIndependent Non Exe. Director164Mar 26
K B S AnandIndependent Non Exe. Director132Mar 26
Punita LalIndependent Non Exe. Director122Mar 26
M D GuptaChairperson59Mar 26
Anand KripaluIndependent Director20Mar 26
Amit Kumar Gupta.Company Sec. & Compli. Officer-Mar 26

Lupin Brands

Brands owned by Lupin

LOGOBRAND NAME
BUDATE FORTE TRANSPULE
SALBAIR TRANSCAPS (DPI)
CEFAXONE 1000 MG
NOVASTAT 5MG
LOGOBRAND NAME
SALBAIR-B TRANSCAPS (DPI)
SALBAIR-I (MDI)
SALBAIR TRANSCAPS (DPI)
SALBAIR NEB TRANSPULES 0.63 (3X7X2.5ML)
LOGOBRAND NAME
OPTINEURON INJ
OPTINEURON FORTE TABLETS
PERCIN
RABLET 10 MG
LOGOBRAND NAME
Clopitab-A
Clopitab-CV
Ramistar
Ramistar-A
Website: www.lupin.com/

About the company - Business Profile

Lupin Limited is a multinational pharmaceutical company with a significant presence in the global generics market and a strong leadership position in India. The company focuses on developing and delivering a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It maintains a robust market position in therapeutic areas such as cardiovascular, diabetology, asthma, pediatric, gastrointestinal, anti-infective, and non-steroidal anti-inflammatory drugs (NSAIDs). Lupin’s operations span across over 100 countries, with key markets including the United States, India, Europe, and emerging economies.

Key Points

Key Facts and Operations

  • Founded Year: 1968.
  • Headquarters: Mumbai, Maharashtra, India.
  • Stock Listing: Listed on the National Stock Exchange (NSE) and BSE Limited.
  • Operations: Operates multiple manufacturing facilities across India (including Tarapur, Pune, Mandideep, Goa, Nagpur, and Aurangabad) and international locations such as Somerset, USA. The company has a total workforce of over 24,000 employees.
  • Market Position: 3rd largest in the U.S. by prescriptions, 7th largest in the Indian Pharma Market, and the 14th largest generics company globally by sales as of FY25.

Revenue and Financial Performance Lupin reported significant financial growth in FY25, driven by its North American and Indian operations.

  • Total Revenue (FY25): INR 221,921 Million.
  • EBITDA (FY25): INR 54,792 Million.
  • Net Profit (FY25): INR 32,816 Million.

Revenue Breakdown by Region (FY25):

  • United States: INR 79,975 Million (36%)
  • India: INR 75,773 Million (34%)
  • Other Developed Markets: INR 29,047 Million (13%)
  • Emerging Markets: INR 25,354 Million (11%)
  • API: INR 11,772 Million (5%)

Key Products and Technology Advancements Lupin specializes in complex generics and specialty platforms. Notable technology and product highlights include:

  • Complex Generics: Accounted for 55% of North American revenue in FY25.
  • Inhalation and Biosimilars: Strategic focus on respiratory products and biosimilars, with a goal to complete three biosimilar filings in regulated markets by 2028.
  • Innovative Platforms: Development of a Long-Acting Injectable platform through its subsidiary Nanomi.
  • Strategic Acquisitions: Acquired diabetes products from Boehringer Ingelheim and Eli Lilly's Humulin in India to strengthen its chronic therapy portfolio.

Business Model and Strategic Initiatives Lupin’s business model is built on vertical integration, ranging from API manufacturing to finished formulations. It excels in chronic therapy management, where it consistently outperforms market growth rates.

  • Chronic Focus: Chronic therapies contribute approximately 65% of its India business. The company holds top rankings in Respiratory (#2), Diabetes Care (#3), and Cardiac (#3) segments in India.
  • Strategic Expansion: Recent initiatives include the expansion of the "Extra-Urban" division (Uday) to increase market reach and collaborations with retailers for the generics business.
  • Quality and Compliance: The company is focused on achieving "Satisfactory" compliance status across all sites, recently receiving successful EIR (Establishment Inspection Report) for its Somerset and Pithampur Unit-III facilities.
  • R&D Commitment: Invested INR 17,672 Million in R&D during FY25, with 848 active patent applications and 453 ANDA/NDA filings with the U.S. FDA.

Sustainability and Future Outlook Lupin has set high benchmarks in sustainability, achieving an S&P Global ESG Rating of 91/100 in 2025. The company aims to launch 10 novel complex pipeline products in India by 2028 and continues to focus on digitalization through its "Lupin Digital Health" initiative for cardiac patient care and neuro-rehabilitation.

References

  1. Annual Report May 2025
  2. Investor Presentation Nov 2025
  3. Investor Presentation Feb 2026
  4. Annual Report May 2024

Lupin FAQ

Lupin today is trading in the green, up by 1.06% at ₹2,011.
Lupin is currently trading up 1.06% on an intraday basis. In the past week the stock rose 4.26%. Stock has been down 16.94% in the past quarter and rose 3.35% in the past year. You can view this in the share price history/seasonality section.
Lupin is listed on NSE with the ticker LUPIN and on BSE as 500257. It's currently trading on NSE at a share price of ₹2,011 and on BSE with a share price of ₹2,009.
The market cap of Lupin is ₹91,961.62 Cr. as of Oct 30, 2026.
Lupin announced a FINAL dividend of 900% which equals ₹18 in Jul 17, 2026.The last three ex-dates for Lupin were Jul 25, 2025, Jul 16, 2024 and Jul 14, 2023. To view the full dividend history of Lupin click here.
Lupin has undergone 1 stock split and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Lupin stock split was on Aug 27, 2010 at a ratio of 10:2 and the last bonus share announcement was on Aug 11, 2006 at a ratio of 1:1.
Lupin reported ₹8,407.21 Cr. in revenue, ₹1,415 Cr. in net profit, and ₹2,579.87 Cr. in EBITD as of Aug 06, 2026 for Q1 FY26-27.
According to the predictions of 36 analysts, the share price prediction for Lupin is ₹2,446.14 with an upside of 22%.
The PE ratio of Lupin is 16.63 as of Oct 30, 2026.
The PB ratio of Lupin is 3.85 as of Oct 30, 2026.
You can view the latest analyst reports on the Lupin reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×